Skip to main content

Table 2. Side effects for each study patient and Ki67 result

From: A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors

  1. *Patient 7 dropped out of the study
Back to article page

Translational Medicine Communications

ISSN: 2396-832X

Contact us